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Abstract
More and more transcription factors and their motifs have been reported and linked to specific gene expression levels.
However, focusing only on transcription is not sufficient for mechanism research. Most genes, especially in eukaryotes, are
alternatively spliced to different isoforms. Some of these isoforms increase the biodiversity of proteins. From this viewpoint,
transcription and splicing are two of important mechanisms to modulate expression levels of isoforms. To integrate these
two kinds of regulation, we built a linear regression model to select a subset of transcription factors and splicing factors for
each co-expressed isoforms using least-angle regression approach. Then, we applied this method to investigate the
mechanism of myelodysplastic syndromes (MDS), a precursor lesion of acute myeloid leukemia. Results suggested that
expression levels of most isoforms were regulated by a set of selected regulatory factors. Some of the detected factors, such
as EGR1 and STAT family, are highly correlated with progression of MDS. We discovered that the splicing factor SRSF11
experienced alternative splicing switch, and in turn induced different amino acid sequences between MDS and controls.
This splicing switch causes two different splicing mechanisms. Polymerase Chain Reaction experiments also confirmed that
one of its isoforms was over-expressed in MDS. We analyzed the regulatory networks constructed from the co-expressed
isoforms and their regulatory factors in MDS. Many of these networks were enriched in the herpes simplex infection
pathway which involves many splicing factors, and pathways in cancers and acute or chronic myeloid leukemia.
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proportion of proteomic complexity in higher eukaryotes. The
mRNA isoforms produced by this alternative processing comprise
of different combination of exons, and may differ in structure,
function, and other properties [3,4]. Different mRNA isoforms are
translated into different protein isoforms (if they exist) which may
have related, distinct or even opposing functions.
The alternative splicing process is regulated by many types of
RNA binding proteins, especially the heterogeneous nuclear
ribonucleoproteins (hnRNP) and the serine/arginine-rich (SR)
family. In eukaryotic cells, hnRNP proteins participate in almost
all pre-mRNA processing steps including splicing, mature mRNA
export, localization, translation, and stability [5,6]. SR proteins are
involved in regulating and selecting splice sites in eukaryotic
mRNAs. These proteins, either ‘classical’ SR proteins or
additional SR proteins [7], generally have at least one RRM
(RNA recognition motif) domain for RNA binding and a Cterminus RS domain for controlling interactions with other
proteins (including other SR proteins). In addition to alternative
splicing, the SR proteins are also involved in mRNA nuclear
export and mRNA translation. One of the most important
characteristics of these splicing factors is their functional specificity.
Many animal experiments suggest that the RNA binding ability of
individual SR proteins are sequence-specific and their ability to
regulate alternative splicing is different [8–10].

Introduction
Gene expression levels are highly dependent on the regulation
of transcription factors which mainly bind to the near-promoter
regions to facilitate or block the recruitment of DNA polymerase II
(pol II) and other complexes. Some methods have been proposed
to predict - gene expression using such binding information of
transcription factors [1,2]. Conlon et al. [2]suggested associating
gene expression with the interaction strength between the upper
stream of the gene and motifs of its transcription factors. This
interaction was defined in terms of degree of matching and
occurrences of binding sites. After that, a probabilistic approach
was proposed to infer regulatory rules of transcriptional networks
from gene expression data and DNA sequences [1]. This method
started with finding co-expressed genes, and then extracted a large
number of putative regulatory DNA motifs in these co-expressed
genes. However, these methods only considered transcription
levels extracted from gene array data and lost sight of other
mechanisms such as alternative splicing. Moreover, these methods
may suffer high false positive rate when mining transcription factor
binding sites. To control the rate of false positive, integrating
information from other kinds of data, like conservation data, is also
necessary.
Alternative splicing is one of the most versatile mechanisms of
gene expression regulation and accounts for a considerable
PLOS ONE | www.plosone.org
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Figure 1. Flowchart of proposed method for constructing regulatory networks. Flowchart of proposed method for constructing regulatory
networks: (A). Process raw RNA-seq data, find out deferentially expressed isoforms using Tophat and Cufflinks and cluster these isoforms to get gene
cluster that may be regulated by same TFs and SFs. (B). Construct two dataset, promote region data (PRD) and exon-intron data (EID), for mining the
interaction strength of the TF-isoform interactions and SF-isoform interaction. (C). Use interaction strength to predict the expression levels of isoforms
in a co-expressed group. (D). Link model-selected TFs and SFs with their target genes.
doi:10.1371/journal.pone.0079118.g001

These highly specific and non-redundant characteristics of
splicing factors motivated researchers to look for association
between abnormalities in SR proteins and the development of
human cancers. Although the underlying mechanisms are elusive
and need further studies, splicing factors that regulate specific
pathways in diseases can be treated as putative markers, especially
when their targets in these disease-related pathways have
PLOS ONE | www.plosone.org

experienced alternative splicing and produced different protein
isoforms.
In this study, we built a systematic method to identify
transcription factors and splicing factors that regulated genes to
produce different RNA isoforms in diseases. Our framework
consists of four steps. First, differentially expressed mRNA
isoforms (DEIs) are extracted by comparing abnormal cells and
2
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controls using RNA-seq analysis tools [11]. These DEIs that may
experience abnormal splicing are putative targets of splicing
factors that might function abnormally in disease. Assuming that
co-expressed genes have a good probability of being functionally
related, we clustered these DEIs to co-expressed groups using
hierarchical clustering method. These co-expressed isoforms may
be regulated by the same group of transcription factors (TFs) and
splicing factors (SFs). Since co-expressed mRNAs are more likely
to have their promoter regions bound by common transcription
factors, we constructed a dataset called promoter region dataset
(PRD) to mine the TF-isoform interactions (for example, coexpressed isoforms may also have common splicing factors that
bind to the regions near their splicing sites). We then constructed
an exon-intron (centered at splicing sites and extending 200 bp on
both sides) dataset (EID) to explore SF-isoform interactions. The
binding strength of the TF-isoform interactions is quantified by
scoring the transcription factor’s binding sites in the promoter
region. Similarly, the binding strength of the SF-isoform interactions is defined by scoring the splicing factor’s binding sites in the
exon-intron regions of pre-mRNA. To integrate both kinds of
regulation, we built a linear regression model and selected a subset
of transcription factors and splicing factors that can regulate the
expression of co-expressed isoforms using least-angle regression
(LARS) [12] selection approach.
The proposed method was applied to a RNA-seq dataset
comprising of 4 myelodysplastic syndromes (MDS) samples (RAEB
subtype) and 5 matched controls. MDSs are defined as clonal stem
cell disorder characterized by ineffective hematopoiesis and
impaired difference in some bone marrow lineages, leading to
peripheral-blood cytopenias. According to the WHO [13], the
main categories of MDS include refractory cytopenia with
unilineage dysplasia (RA), refractory cytopenia with ringed
sideroblast (RARS), refractory cytopenia with multi-lineage
dysplasia (RCMD), refractory cytopenia with excess blasts
(RAEB), 5q-syndrome and unclassifiable MDS. In this paper, we
focused on RAEB cases which are characterized by 5–20%
myeloblasts in the marrow [14]. This is a higher risk subtype and
likely to transform to acute myelogenous leukemia (AML).
Some work studied the genetic abnormality of MDS with
mutations of key genes [15], e.g. TP53 and RUNX, which are
highly related with poor overall survival. Recently, the recurrent
mutation of splicing factor U2AF1 has been validated for MDS
patients [16]. In-vitro experiments demonstrated that the mutated
U2AF2 enhances splicing and promotes exon skipping. These
genetic aberrations would improve the prediction of prognosis and
development of novel treatment. However, mutation detection
cannot determine which genes are altered due to the abnormality
of splicing factors. Our method can recognize not only isoforms
that experience an abnormal splicing process but also their
putative regulatory factors. The co-expressed isoforms and their
transcription and inferred splicing factors comprise our transcription and splicing networks.
To verify the biological significance of these regulatory networks
composed of a group of co-expressed isoforms and their regulatory
factors in MDS, we showed theses networks were significantly
enriched (p,0.0001) in some known Gene Ontology (GO) biology
processes and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways. Enrichment analysis demonstrated that more
than half of these networks were enriched in herpes simplex
infection due to involving many splicing factors. Six networks were
significantly related with pathways in cancer, and five networks
were significantly related with acute or chronic myeloid leukemia
(AML).

PLOS ONE | www.plosone.org

Methods
Our four-step framework (Figure 1) starts with raw RNA
sequencing (RNA-seq) data. First, differentially expressed isoforms
(DEIs) are identified from a large amount of isoforms. We cluster
these DEIs into co-expressed groups that may be regulated by
common TFs and SFs (Figure 1A). At the second step, two
datasets, promoter region data (PRD) and exon-intron data (EID),
are constructed, where the PRD dataset is used for mining the
interaction strength between TFs and isoforms and the EID is used
for exploring the interaction strength between TFs and isoforms
(Figure 1B). This step outputs two interaction strength matrices
with rows corresponding to isoforms and columns corresponding
to TFs or SFs. Then, by taking the interaction strength matrices as
observations of explanatory variables, we build linear model to
regress the expression levels of isoforms in a co-expressed group.
To detect the most important factors that regulate a co-expressed
group, a reliable model selection method called least-angle
regression (LARS) is applied (Figure 1C). At the final step, the
TFs and SFs selected by the LARS are linked with their target
genes, forming regulatory networks (Figure 1D).

Ethics Statement
This study was approved by the Institutional Review Board of
The Methodist Hospital, Houston, Texas, USA and the need for
written informed consent from the participants was waived by the
IRB.

Data Preprocessing and Co-expressed Isoforms
RNA samples were prepared from 9 individuals, 4 samples from
RAEB patients and 5 controls (http://ctsb.is.wfubmc.edu/MDS/
MDS.html). After sequencing using Genome Analyzer II (GAII)
(Illumina, San Diego, CA), millions of reads were produced for
each sample. The raw data were processed using a RNA-seq
analysis pipeline [11]. Briefly, reads in the FASTA format were
first aligned to whole genome using TopHat software. Since our
sequencing data are pair-ended, the fragments were selected at
350 bp and the length of reads was 76, the inner distance between
mate pairs was set as 198. The standard deviation for the
distribution on inner distances between mate pairs was set as 30
based on our estimation. Then Cufflinks was called to estimate the
expression level (RPKM, reads per kilobase of transcript per
million mapped reads) of each isoform. Then, Cuffdiff was used to
identify differentially expressed isoforms (using default parameters). This protocol returned 1056 isoforms that were differentially
expressed in MDS compared with controls. Before using these
DEIs to build splicing networks, we first filtered out those isoforms
that had not been validated at the protein level. Then, we checked
the condition (control or MDS) in which an isoform was upregulated and required that all FPKM values under this condition
were higher than 5 [17].
Although there are debates on whether co-expressed genes are
functionally related, numerous studies have suggested that at least
some co-expressed clusters function together [18–20]. Here we
applied hierarchical cluster analysis to those differentially expressed isoforms to obtain co-expressed groups. The distances
between genes were defined as Pearson correlation. Allocco et al.
[21] concluded that genes with strongly co-expressed mRNAs
were more likely to have their promoter regions bound by
common transcription factors. However, this co-regulating effect
was significant only when expression of these co-expressed
mRNAs were highly correlated. To control the similarity level of
expression profiles of isoforms in the same group, we limited the
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EPS15, RAB13, ERLIN1, CAT, CWC15, RPL6, EID1, SEC11A, CKLF, RPL23, RPL19, FBXO7,
EIF3L, POLR2B, RPL34, RPS3A, RPS6, CNTRL, EIF2S3, IK, HMGN4

FUBP1, UFC1, HNRNPU, CHD4, ETV6, FGFR1OP2, PFDN5, NCKAP1L, NACA, NAP1L1, CTCF,
GLOD4, ZNF830, RPL38, SAFB2, CEBPZ, CEP63, USO1, HNRNPD, PPWD1, NSA2, RPS23,
HINT1, SKP1, RPS12, EIF3H, CEP350, ARID4A, PRPF40A, ST13, STXBP3, SERTAD2, CNBP

PHTF1, H3F3C, TRIAP1, PMAIP1, KLF2, EEF1B2, IL8, HNRPDL, ARRDC3, FKBP5, NAMPT

MAN1A2, IFI16, UPF2, FGFR1OP2, FLT3, TERF2IP, LRRFIP1, EGR1, MLL5, TMEM66,
IRF2BP2, ITSN2, PRRC2C, STT3B, CD164, SPRY1

HIST2H2BE, SLC2A3, SRSF5, TEC, PTP4A1, ESYT2, LYN, SMARCA2, JMJD1C, PIM3, KLF10

ANP32E, ILF2, COX4I1, AATF, MPO, SNRPD1, FBL, RPS19, SNRPD2, RPL18,
PPM1G, RPS21, GCFC1, CCDC72, H2AFZ, COX6C, DKC1

GATAD2B, GDI2, APBB1IP, RPS13, HNRNPA1, LTA4H, MFAP1, ME2, MYADM, SEPT2,
C21orf59, RUNX1, RPL35A, SNX2, HSPA9, PAIP2, LARS, SOX4, POLR2K, STRBP, RPL7A,
SLC25A5, NRD1, LARP1, C19orf77, MRPL3, PNRC2, MTIF3

16

17

18

19

20

21

KHDRBS1, PIP4K2A, RPLP2, SMARCC2, RBM25, RFX7, YWHAQ, XRCC5, VDAC1,
GNB2L1, SHFM1, SMC1A, HDGF, LSM14A, MAT2A

10

15

SRSF4, NASP, SERBP1, CSTF3, SSRP1, ERP29, RAN, HMGB1, SRP14, PSMA4, NUTF2,
RPS16, VAMP8, HSPE1, CCT5, TAF9, HIST1H2BD, HIST1H4E, TUBB, HNRNPA2B1, PPIA, FKBP3

9

NASP, UQCRH, ZRANB2, NUCKS1, FKBP4, ANP32A, EIF3C, PTMA,
SUMO3, HNRNPA2B1, TXN, MYL12B

STMN1, ATPIF1, CFL1, APLP2, SARNP, MLEC, POMP, ERH, FUS, NME1, GNAI2,
HNRNPAB, DEK, HIST1H2BC, HIST1H2AC, HIST1H4H, SEC61G, HIST1H2BK

8

14

TMEM50A, DNAJC8, ZNHIT6, MRPL9, DDX21, RPL36, RPL13A, NOP58, YWHAB,
SREK1, ZMAT2, EIF2AK1, RBM3, UPF3B, HMGB2, SRF

7

GNL2, EIF3M, CD44, FNBP4, OSBPL8, NUFIP2, STK17B, SYPL1, MDM4, ANKRD36B, IER2

SRRM1, JUN, PRDX6, DUSP10, RBM34, HSP90AA1, SRRM2, RPS7, RPL3, RPL32, RPS20

6

THRAP3, PSMB4, ARF3, TCF25, GABARAP, TAF15, CHMP2A, GAR1, C9orf78, ACIN1, UBB, BASP1

PRDM2,GPBP1L1,ZRANB2,DNTTIP2,SMG7,EIF4G2,
PHF21A,RBM4B,GNPTAB,UFM1,
ERCC5,SF3B1,CD47,CDV3,BDP1,
DDAH2,SNX3,PPIL4,KIT,PCMTD1,RABGAP1,DDX3X,C16orf80

4

13

TARDBP, HDAC1, ARHGDIB, ESD, CX-CR4, TTC1, HLA-DPB1, ANP32B, ATP1A1, ARPC5

3

12

PARK7, KDM1A, SSR2, DNTT, HNRNPA1L2, SUPT16H, SLIRP, YWHAE, TAF15, TOP2A,
SRSF1, ATP5A1, EEF1B2, HMGN1, U2SURP, HSD17B4, CANX, MAP7D3, HNRNPM, BCL11A

2

SFPQ, SRSF11, BCAS2, TFAM, ZFP91, CSDA, NGRN, RPS15A, RPL26, NACA2, EEF2,
DDX18, SF3B1, MAPRE1, SATB1, RPL24, SMARCA5, RUFY1, NUP153, DDX39B,
RPL10A, HOXA7, RPL7, TCEAL4, RBMX, SYF2

GNB1, GPATCH4, MRPL51, BRD4, ODC1, ATP5J, HNRNPD, RBBP7, CALM3, ANP32C, PSPC1, SETD3

1

11

Target Genes

No

Table 1. Regulatory networks found by our model.

4

ATF6, Egr-1, ER-alpha, HNF-1alpha, IRF-1, MEF-2, MTF-1,
Nkx2-5, PLZF, RSRFC4, Sp1, Sp3, UF1H3BETA, ZID

LXR direct repeat 4, Nkx2-5, 1-Oct, PPARalpha:RXRalpha,
REST, STAT5A (homodimer), STAT5B, TBX5, UF1H3BETA

Egr-1, Nkx2-5, Pbx1a, Sp1

Egr-1, Nkx2-5, p53, RSRFC4, SRF, STAT1,
STAT5B (homodimer), UF1H3BETA

HNF4, HSF1, MafA, MIG1, PLZF, Sp1, ZID

AIRE, AP-2, ATF6, Blimp-1, Egr-1, Evi-1, KROX,
LXR direct repeat 4, MEF-2, Nkx2-5, 1-Oct, POU3F2,
RSRFC4, Sp1, SRF, ZBRK1

AIRE, COUPTF, Egr-1, Evi-1, FOXP1a, HNF-1alpha,
LXR direct repeat 4, Nkx2-2, Nkx2-5, PLZF, Sp1, SRF,
PPARalpha:RXRalpha, PPARG

AIRE, COUP-TF1, Egr-1, Evi-1, GLI1, MTF-1,
NF-kappaB, STAT5A (homodimer), UF1H3BETA

FOXO3a, POU3F2, TBX5

Egr-1, Gfi1b, NF-Y, STAT5B, UF1H3BETA

ER-alpha, GLI1, KAISO, mat1-Mc, MIG1, MTF-1,
Nkx2-5, Pax-6, PLZF, RSRFC4, Sp1, SRF, STAT1, ZID

AP-2alphaA, ATF6, Egr-1, MTF-1, Nkx2-5, STAT5B, ZID

AP-2alphaA, Egr-1, ER-alpha, Evi-1, GLI1, IRF, MCM1, NIT2,
Nkx2-5, Pbx1a, RSRFC4, STAT1, STAT5A (homotetramer),
UF1H3BETA

AP-2alphaA, Egr-1, HOXA5 (Hox-1.3), MCM1, MTF-1,
NF-Y, Pax-6, PLZF, RXR-alpha, STAT1

Blimp-1, Egr-1, ER-alpha, Evi-1, LXR direct repeat 4,
Nkx2-5, Pax-6, Pbx1a, PLZF

Blimp-1, HNF-1alpha, KROX, MEF-2, Nkx2-5, Sp1

Blimp-1, Egr-1, Evi-1, FOX factors, KROX, NIT2,
Pax-6, POU3F2, RSRFC4, SRF

ATF6, COUPTF, FOX factors, FOXP1d, IRF, Nkx3-1

Egr-1, Evi-1, LXR direct repeat 4,
MEF-2, Nkx2-5, Pax-6, RSRFC4, Sp1

Blimp-1, FOX factors, FOXP1a, Sp1, STAT5B

Transcription Factors

ETR-3, MBNL1, SRp38, SRp54, SRp55,
TIAL1, hnRNPA1/A2, hnRNPE1/E2

hnRNPD, hnRNPU, HTra2alpha, SRp40,
SRp55

PSF

9G8, MBNL1, TIA-1, hnRNPA1/A2,
hnRNPC/C1/C2, hnRNPH1/H2/H3

9G8, KSRP

9G8, hnRNPK, hnRNPP(TLS), hnRNPQ,
hnRNPU, SRp20, SRp30c, SRp38, SRp40,
TIA-1, YB-1, hnRNPA1/A2, hnRNPC/C1/
C2, hnRNPE1/E2

hnRNPP(TLS), KSRP, MBNL1, SF2, SRp55

Sam68

9G8, ETR-3, hnRNPF, hnRNPP(TLS),
SRp20, hnRNPH1/H2/H3

PSF, SC35, SRp40, SRp55

9G8, DAZAP1, hnRNPF, HTra2beta1,
KSRP, MBNL1, SRp30c, TIA-1, hnRNPC/
C1/C2, hnRNPE1/E2

9G8, HTra2alpha, MBNL1, PSF, SC35,
SRp30c

9G8, hnRNPI(PTB), HTra2alpha, SRp30c,
TIAL1

hnRNPF, hnRNPI(PTB), MBNL1, SRp30c,
SRp55, TIAL1

SC35, SF2, SRp40, TIA-1, hnRNPA1/A2

SRp20, SRp54, YB-1

hnRNPQ, KSRP, SF1, SRp38, SRp54,
SRp55, TIA-1, TIAL1, YB-1, hnRNPA1/A2,
hnRNPE1/E2

SRp40, hnRNPE1/E2

ETR-3, hnRNPD, hnRNPI(PTB), hnRNPQ,
MBNL1, PSF, SF2, SRp38, SRp40, hnRNPC/
C1/C2

MBNL1, PSF, Sam68, SF2, SRp38, YB-1

Splicing Factors

Transcription and Splicing Networks in MDS
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5

NXF1, FAU, TAF1D, PPTC7, PABPC3, ELF1, CHD9, JUND, LAPTM4A, RANBP2, HAT1, UBE2D3,
SBDS, FLJ44635, TSC22D3, HSPH1, KPNB1

CCND2, METAP2, ARGLU1, MIS18BP1, CCNK, PSME3, RPL38, GLTSCR2, RPS11, HADHA, RPL31, HSPD1,
RPL37A, NOP56, BRK1, RPL37, UBE2V2

ITM2B, SCAPER, PPIG, MRFAP1L1, RASGEF1B, AIF1, RNPC3, H3F3B, BPTF, AFF1, B3GNT5

NIN, ZNF609, ZFP36L2, SOD1, NOL7, LTB, ITGA6, WDR77, PIM1, SEPT7

31

32

33

34

ABF, Antp, COUP-TF1, ID1, KAISO, myogenin/NF-1, RORalpha1

Alx-4, Blimp-1, BLIMP1, HNF-1alpha, KROX, Sp1

AIRE, AP-2alphaA, dl, Egr-1, HNF-1alpha-A, 1-Oct,
Olf-1, p53, Pax-6, Pbx1a, RSRFC4, Sp1

ER-alpha, ER-beta, GLI1, KROX, Nkx2-5, NRSF, Staf

AIRE, ATF6, FOXO1, Gfi1b, 1-Oct, Sp1

Egr-1, HNF-1alpha, RXR-alpha

BLIMP1, COUP-TF1, Egr-1, HNF-1alpha, IRF, IRF-1, SRF, ZID

Blimp-1, Egr-1, Evi-1, GLI1, MTF-1, NIT2,
Nkx2-2, Pax-6, PLZF, ZID

AP-2, BLIMP1, KROX, MEF-2, Sp3, STAT5B

AIRE, Evi-1, FOXO3a, IRF-3, MEF-2, VDR, CAR, PXR

E2F-1:DP-2, Egr-1, GLI1, HNF-1alpha, IRF, IRF-3, KROX,
mat1-Mc, MEF-2, MyoD, NF-kappaB, NIT2, Nkx2-5,
NRSF, RSRFC4, Sp1, ZID

Transcription Factors

hnRNPK

hnRNPF, SRp40, hnRNPA1/A2

SC35, SRp38, hnRNPE1/E2

HTra2alpha, Sam68, SRp30c, SRp38,
SRp55, hnRNPA1/A2

hnRNPF, SRp20, TIA-1

ETR-3, hnRNPK, SRp55

YB-1

DAZAP1, hnRNPD, hnRNPI(PTB), MBNL1,
SRp20, SRp30c, YB-1, hnRNPA1/A2,
hnRNPE1/E2

Sam68, hnRNPA1/A2

hnRNPD

hnRNPI(PTB), KSRP, SF2, SRp20, SRp30c

Splicing Factors

The first column is differentially expressed isoform groups in our cases, the second and third columns are the Transcription factors and splicing factors predicted by our regression model. Some cells are blank, which means no
corresponding factors for that co-expressed group.
doi:10.1371/journal.pone.0079118.t001

PSMA1, NEDD8, ADAM10, PSMC5, UBE2G2, PDCD10, SEC62, CWC27, LCP2, XPO7, PEBP1

30

HNRNPU, SAP18, RBM26, LEO1, UQCRC2, RPL27, RPS9, DUSP11, DARS, ARPC2, ESF1, SERINC3,
PITPNB, HNRNPA0, TCERG1, NPM1, C6orf48, IL2RG, RPS4X, API5, SEP15, RPL23A

25

PDLIM1, LMO2, C11orf67, SLC38A1, DUSP6, ROCK2, KIF2A, PHF3, CD164, TAX1BP1, SEPT6, DDX1

RGS2, CD34, RSF1, WNK1, CBFB, CSTB, IQGAP2, GNAI1, LAPTM4B, SH3KBP1, HNRNPM, ARCN1, MARCH6

24

EIF4EBP2, CELF1, ATXN7L3B, PRPF8, RPSA, SRP72, DDX46, STK38, SRSF3, NGFRAP1, TOP2B

RGS1, PTMS, PARP2, C16orf61, CLK1, EAF2, SLU7, RSRC2, ZCCHC7

23

28

SELL, TMEM123, DDX6, TMBIM6, CASC4, B2M, CHD2, USP34, SETD2, PAK2, HSD17B11, GOLPH3,
DFIP1, WRNIP1, UTRN, VAMP2, PCM1, SORL1, PAN3, ATXN3, XRN2, FBXO11, C4orf3, GAPT

22

27

Target Genes

No

Table 1. Cont.
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Table 2. Names and description of splicing factors used in our model.

Splicing Factors

Gene Name

Description

9G8

SRSF7

Splicing factor arginine/serine-rich 7. The shuttling protein 9G8 binds TAP and can function as export factors.

CUG-BP1

CUGBP1

CUG triplet repeat RNA binding protein 1. CUGBP1 induces exon 5 inclusion in cTNT gene (PMID: 9563950), induces
exon 11 exclusion in IR gene (PMID: 11528389), induces intron 2 retention in CIC-1 gene (PMID: 12150906).

DAZAP1

DAZAP1

DAZ associated protein 1.

ETR-3

CUGBP2

CUG triplet repeat RNA binding protein 2. ETR-3 induces exon 5 inclusion in cTNT gene (PMID: 11931771), induces exon
9 inclusion in CFTR gene (PMID: 15657417), promotes selectively the exclusion of Tau exon 2 (PMID: 16862542).

hnRNP A1

HNRNPA1

Heterogeneous nuclear ribonucleoprotein A1. hnRNP A1 carries bidirectional shuttling signals that serve for both
nuclear localization and export (PMID: 8521471)

hnRNP A2/B1

HNRNPA2B1

Heterogeneous nuclear ribonucleoprotein A2/B1. hnRNP A2 is involved in cytoplasmic RNA transport (PMID: 11024030).

hnRNP C

HNRNPC

Heterogeneous nuclear ribonucleoprotein C. Tetramer composed of 3 copies of isoform C1 and 1 copy of isoform C2.
hnRNP C proteins are restricted to the nucleus because they bear a nuclear retention sequence (NRS) (PMID: 8830767).

hnRNP C1

HNRNPC

Heterogeneous nuclear ribonucleoprotein C. Isoform C1 is due to Alternative Splicing.

hnRNP C2

HNRNPC

Heterogeneous nuclear ribonucleoprotein C. Isoform C2 is due to Alternative Splicing.

hnRNP D

HNRNPD

Heterogeneous nuclear ribonucleoprotein D.

hnRNP D0

HNRNPD

Heterogeneous nuclear ribonucleoprotein D. Isoform D0 is due to Alternative Splicing.

hnRNP DL

HNRNPDL

Heterogeneous nuclear ribonucleoprotein D-like.

hnRNP E1

PCBP1

Holy(rC) binding protein 1.

hnRNP E2

PCBP2

Holy(rC) binding protein 2.

hnRNPF

HNRNPF

Heterogeneous nuclear ribonucleoprotein F.

hnRNPH1

HNRNPH1

Heterogeneous nuclear ribonucleoprotein H1.

hnRNPH2

HNRNPH2

Heterogeneous nuclear ribonucleoprotein H2.

hnRNPH3

HNRNPH3

Heterogeneous nuclear ribonucleoprotein H3.

hnRNP I(PTB)

PTBP1

Polypyrimidine tract binding protein 1. In the context of CALCA gene, PTB enhances exon 4 inclusion (PMID: 9858533).
nPTB functionally compensates for PTB and is up-regulated when PTB is removed (PMID:17679092).

hnRNP J

HNRNPK

Heterogeneous nuclear ribonucleoprotein K. isoform J is due to Alternative Splicing.

hnRNP K

HNRNPK

Heterogeneous nuclear ribonucleoprotein K. hnRNP K carries bidirectional shuttling signals that serve for both nuclear
localization and export (PMID: 9218800).

hnRNP M

HNRNPM

Heterogeneous nuclear ribonucleoprotein M.

hnRNP P(TLS)

FUS

Fusion (involved in t (12, 16) in malignant liposarcoma).

hnRNP Q

SYNCRIP

Synaptotagmin binding cytoplasmic RNA interacting protein.

hnRNP U

HNRNPU

Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A).

HTra2alpha

TRA2A

Transformer-2 alpha.

HTra2beta1

SRSF10

Splicing factor arginine/serine-rich 10.

KSRP

KHSRP

KH-type splicing regulatory protein.

MBNL1

MBNL1

Muscleblind-like. MBNL proteins can act as activators or repressors of splicing on different pre-mRNAs (PMID:
15257297). MBNLs are dsRNA binding factors that can bind CUG or CCUG repeats (PMID: 14722159).

PSF

SFPQ

Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated).

RBM25

RBM25

RNA binding motif protein 25. RBM25 stimulated proapoptotic Bcl-X(s) isoform through weak 59ss selection in EX2
(PMID: 18663000).

RBM4

RBM4

RNA binding motif protein 4. RBM4 induce exon inclusion of alpha-TM EX9a and EX2b (PMID: 16260624) and tau EX10
(PMID: 16777844).

RBM5

RBM5

RNA binding motif protein 5.

Sam68

KHDRBS1

KH domain containing RNA binding signal transduction associated 1.

SC35

SRSF2

Splicing factor arginine/serine-rich 2. SC35 accelerates transcriptional elongation (co-transcriptional splicing) (PMID:
18641664).

SF1

SF1

Splicing factor 1. Gomafu lncRNA UACUAAC repeats bind to mouse SF1 with a higher affinity than the mammalian
branch point consensus regulating splicing efficiency by changing the splicing factors nuclear level (PMID: 21463453)

SF2

SRSF1

Splicing factor arginine/serine-rich 1 (splicing factor 2, alternate splicing factor). The shuttling protein SF2/ASF binds
TAP and can function as export factors (18364396).

SRp20

SRSF3

Splicing factor arginine/serine-rich 3. The shuttling protein SRp20 binds TAP and can function as export factors
(18364396).

SRp30c

SRSF9

Splicing factor arginine/serine-rich 9.
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Table 2. Cont.

Splicing Factors

Gene Name

Description

SRp38

FUSIP1

FUS interacting protein (serine/arginine-rich). Dephosphorylation converts SRp38 to a splicing repressor (PMID:
12419250). SRp38 functions as a general splicing repressor when dephosphorylated, but when phosphorylated it
functions as a sequence-specific splicing activator (PMID: 18794844).

SRp40

SRSF5

Splicing factor arginine/serine-rich 5.

SRp54

SRSF11

Splicing factor, arginine/serine-rich 11.

SRp55

SRSF6

Splicing factor arginine/serine-rich 6.

SRp75

SRSF4

Splicing factor arginine/serine-rich 4.

TDP43

TARDBP

TAR DNA binding protein. It can act as transcriptional repressor (21252238).

TIA-1

TIA1

Cytotoxic granule-associated RNA binding protein.

TIAL1

TIAL1

TIA1 cytotoxic granule-associated RNA binding protein-like 1.

YB-1

YBX1

Y box binding protein 1.

ZRANB2

ZRANB2

Zinc finger, RAN-binding domain containing 2. ZRANB2 (ZNF265) is an SR-like protein that induce exclusion of EX2 and
EX3 from the Tra2beta1 pre-mRNA in HEK293 cell (PMID: 11448987).

This table contains 22 splicing factors which are selected to predict the expression levels of differentially expressed isoforms. This table lists their names and some
related references. Most of these details are from SpliceAid.
doi:10.1371/journal.pone.0079118.t002

and sa2 are regression coefficients; (:)T is transposition operator;
TF
S(TFs)~(S1TF ,S2TF ,    ,SM
) are binding strength vectors of
1
transcription factors; M1 is the number of transcription factors;
SF
) are binding strength vectors of
S(SFs)~(S1SF ,S2SF ,    ,SM
2
splicing factors; M2 is number of splicing factors and e is the
error term.
To estimate the binding strength between TFs and isoforms, we
first constructed a promoter region database (PRD, Figure 1B)
comprised of promoter sequences of isoforms. As in previous study
[25], we extracted 2000 bp upstream of the transcription start sites
as promoter regions. Similarly, we constructed an exon-intron
dataset (EID, Figure 1B) to estimate the binding strength
between SFs and isoforms. Most splicing factor binding sites
locate near the splicing sites [26], especially 200 bp on both sides
of this site. Therefore, for isoforms with alternative splicing, we
gathered 200 bp of sequences around their splicing sites into EID
to find splicing factor binding sites.
Based on the PRD and EID, we could define the TF-isoform
interaction strength and SF-isoform interaction strength. First, we

size of each group to be between 10 and 30 [19,22]. In our MDS
study, this resulted in 34 clusters (Table 1).

Mathematic Modeling
Transcription factors regulate transcription, which controls gene
expression. Splicing factors regulate alternative splicing, which
splices pre-mRNA to RNA isoforms and in turn changes protein
expressions [23]. Some predictive methods have modeled gene
expression levels as a linear function of occurrences of TF-binding
sites (TFBSs) [2,24]. In this paper, we focus on RNA isoforms
instead of genes and try to link isoform expression levels not only
with the transcriptional factors but also with splicing factors.
Isoform expression levels were formulated as linear regression of
the strength of TF-isoform interactions and SF-isoform interactions, given by
E(g)~a0 za1 T  S(TFs)za2 T  S(SFs)ze,

ð1Þ

where, g is an isoform; E(:) denotes the expression level; a0 , a1
Table 3. Pseudocode of LARS algorithm.

LARS algorithm
Data: Normalized expression levels of co-expressed isoforms YN|1 , normalized interaction strength matrix XN6P
Output: Regression coefficients aP61
All coefficients ai (i~1,    P) equal to zero;
Active set A~1;
Find predictor xj1 most correlated with YN61;
Let direction D~xj1 ;
Repeat
^ ;
Adjust the coefficient in the direction D at the highest step possible until some other explanatory variable xjm has the same absolute correlation residual r~Y {Y
Put xjm in A;
Let D in the direction that is equiangular with xj1 ,xj2 ,    ,xjm
Until P{1 variables have entered the active set
doi:10.1371/journal.pone.0079118.t003
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downloaded TF motif models (PWM, position weight matrixes)
from TRANSFAC [27] and JASPAR [28]. Then, for each TF, a
hidden markov model based method called MAPPER [29] was
used to identify its sites (TFBSs) in PRD. For each binding site, the
MAPPER also outputs a binding score measuring the binding
affinity. TFs with no hits on PRD were removed. After retrieving
all putative binding sites and their binding scores, we defined the
interaction strength between a TF j and a RNA isoform i as
STFij ~mean(Sij,1 ,Sij,2 ,Sij,3 ,    ,Sij,N ). Where, Sij,n is the score of
n-th binding site between i-th isoform and j-th transcription factor;
and N is the number of binding sites.
Unlike TFs, SFs lack a reliable PWM database available. Thus,
we gathered 53 splicing factors that are related with bone marrow
cancers and their binding motifs from the SpliceAid [30]
repository. This database collects all the experimentally assessed
motifs that are bound by splicing factors in humans by means of an
exhaustive literature search. Motifs with positive scores facilitate
exon definition as exonic splicing enhancers (ESEs) or intronic
splicing silencers (ISSs) motifs, while motifs with negative scores

Table 4. Target genes and corresponding factors in networks 1.

TFs

Coefficients SFs

Target
Coefficients genes

Blimp-1

0.0341

Sam68

1.082

GNB1 PSPC1
ATP5J SETD3

Sp1

20.303

SF2

0.106

GPATCH4
HNRNPD

Fox factors 0.023

SRp38

20.6486

MRPL51
RBBP7

FOXP1a

20.387

MBNL1

21.106

BRD4
CALM3

STAT5B

20.012

PSF

20.681

ODC1
ANP32C

Adjusted
R

0.991

This table lists the target genes and factors that regulate them. The regression
coefficients are listed on the right side.
doi:10.1371/journal.pone.0079118.t004

Figure 2. Expression ratio of SRSF11’s three isoforms (A), motifs in SRSF11’s isoforms and classical SR proteins (B), RT-PCR results
(C) and protein Expression of SRSF11. (A). Expression ratio of SRSF11’s three isoforms in seven disease sample and control: uc009wbj.1 (light
green), uc001deu.2 (light blue) and uc001.dev.3 (light red). They have almost the same total expression levels but very different ratios in MDS (four )
and control (average of five controls), which means the splicing patterns of SRSF11 are switched. (B). This figure demonstrates motifs in SRSF11’s
isoforms and classical SR proteins. Different motifs have different bio-function. (C). Three isoforms that are over-expressed in our disease samples are
picked up for RT-PCR validation. They are isoforms of three splicing factor, one isoform (uc001deu.2, refseq ID: NM_001190987) of SRSF11, one
isoform (uc001xlp.3, refseq ID: NM_006925) of SRSF5 and one isoform (uc003jun.2, refseq ID:NM_080743) of SRSF12. Validation demonstrated that
their expression levels in MDS disease are higher than in control. (D). Isofrom uc001deu.2 is translated into protein Q05519 and Q05519 is highly
expressed in blood disease according to the Model Organism Protein Expression Database (MOPED); COPD: Chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0079118.g002
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Table 5. Results of enrichment analysis using KEGG database.

No.

Pathway

Regulatory Network

1

Herpes simplex infection

NT2, NT6, NT7, NT8, NT9, NT10, NT11, NT12, NT13, NT15, NT16, NT18, NT20, NT22, NT25,
NT31

2

Pathways in cancer

NT8, NT9, NT14, NT15, NT18, NT20

3

Chronic myeloid leukemia

NT9, NT14, NT18, NT22

4

Maturity onset diabetes of the young

NT15, NT25, NT32

5

Acute myeloid leukemia

NT18, NT20

6

PPAR signaling pathway

NT15, NT20

7

Pertussis

NT8, NT22

8

Transcriptional mis-regulation in cancer

NT15

9

Jak-STAT pathway

NT18

This table lists top enriched KEGG pathways and corresponding networks number.
doi:10.1371/journal.pone.0079118.t005

between a SF and an isoform, SSFij ~mean(Sij,1 ,Sij,2 ,Sij,3 ,    ,
Sij,N ), where, Sij,n is the conservation score of n-th binding site
between i-th isoform andj-th splicing factor; SSFij is the interaction
strength between j-th splicing factor and i-th isoform; Nis the
number of binding sites. Some factors, especially the hnRNP
family, are due to alternative splicing, for example hnRNP H1,
hnRNP H2 and hnRNP H3, which means they may have similar
structure [32],motifs [33] and binding profiles. After we computed
their interaction strength with isoforms according to our definition,
the correlation between interaction strength vectors were high. To
increase the robustness of our linear regression model, we
averaged the binding strength and obtained four new factors,
called hnRNP A1/A2 (average of hnRNP A1 and A2), hnRNP
H1/H2/H3(average of hnRNP H1, H2 and H3), hnRNP C/C1/
C2 (average of hnRNP C, C1 and C2) and hnRNP E1/E2
(average of E1 and E2).
Integrating all these binding strength, the results were two
interaction strength matrices with rows corresponding to isoforms
and columns corresponding to TFs or SFs. These were bound

facilitate intron definition as exonic splicing silencers (ESSs) and
intronic splicing enhancers (ISE) motifs. The absolute values of
these scores measure the levels of binding affinity. To control false
positive rate, we filtered out motifs with absolute scores less than 5
and lengths longer than 15. Finally, 49 out of 53 splicing factors
are selected (see Table 2). Since motifs of these splicing factors are
degraded short pieces (6 to 10 base pairs on average), when
retrieving all binding sites of these SFs using alignment tool Bowtie
[31], we got numerous hits, most of which were false positives. To
identify putative binding sites with high reliability, we downloaded
base-wise conservation scores (phyloP) by comparing 45 vertebrate
genomes with human genome from the UCSC Genome Browser
website (http://genome.ucsc.edu/). We defined the conservation
score of a hit as the average conservation score of the nucleotides it
spanned. Hits with scores lower than 2 were deleted. Though
conversion score is not directly related with interaction strength, a
highly conserved binding site on an isoform does provide evidence
of a strong interaction. We further averaged conservation scores of
all hits of a splicing factor on an isoform to eliminate the effect of
exon numbers. This average is defined as interaction strength
Table 6. Results of enrichment analysis using GO database.

Network
6

Biological Process

P value

mRNA splicing, via spliceosome

5.8e-05

leading edge cell differentiation

2.2e-05

ERK5 cascade

3.9e-6

10

mRNA splice site selection

8.8e-05

11

regulation of RNA splicing

1.2e-05

positive regulation of mRNA splicing, via spliceosome

5.5e-05

positive regulation of transcription initiation from RNA polymerase II promoter

7.4e-06

positive regulation of neural precursor cell proliferation

3.8e-05

15

16

mRNA 59-splice site recognition

2.9e-05

regulation of muscle cell differentiation

1.3e-07

transcription from RNA polymerase II promoter

3.1e-05

termination of RNA polymerase II transcription

3.8e-05

mRNA 39-end processing

1.0e-07

multi-organism reproductive process

4.7e-06

Three networks enriched in some GO biological processes. This table lists the details and the P values.
doi:10.1371/journal.pone.0079118.t006
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Figure 3. Connected regulatory network for network 18. Connected regulatory network for network 18. Red nodes are transcription factors,
blue nodes are splicing factors and gray nodes in the middle are targets. The connection between targets is from IPA and the connection between
factors and targets are from our interaction strength matrix.
doi:10.1371/journal.pone.0079118.g003

capability better, to selected TF and SF factors that regulated each
group of co-expressed isoforms. The LARS algorithm is summarized in Table 3.

together to build linear regression model in equation (1) to fit
isoform expression levels (Figure 1C).

Model Selection
Biological Significance of these Regulatory Networks

The dependent variable (isoform expression) and explanatory
variables (interaction strength value of factors) in the linear
regression model in (1) were all normalized. Many methods such
as ordinary least squares (OLS), ridge regression with a L2 norm
penalization [34], LASSO with a L1 norm term [35], and Leastangle regression (LARS), can be adopted for optimization and
selection of linear model. However, when the number of
explanatory variables is higher than number of observations, it is
more critical to balance regression accuracy and interpretation
capability. Unfortunately, the OLS method incurs both regression
accuracy and interpretation ability problems. Ridge regression
fails to achieve a parsimonious set of predictors, which may lead to
stable regression accuracy but a poor interpretation of model.
LASSO, in which a L1 norm penalization term is employed, helps
to improve both issues. However, it adopts quadratic programming techniques to solve a constrained optimization problem,
which may limit its application when the sample size is small with
respect to the number of explanatory variables. Therefore, in this
paper, we adopted a promising model selection method called
LARS [12], which can balance the accuracy and interpretation

PLOS ONE | www.plosone.org

At the last step of the flowchart in Figure 1, a transcription and
splicing network (TSN) was constructed with a group of coexpressed isoforms and the selected TFs and SFs using the method
described above. To validate the biological significance of these
regulatory networks we conducted a comprehensive functional
enrichment analysis.
First, we studied the enrichment of these inferred regulatory
networks in the KEGG pathway [36]. The KEGG database is a
collection of manually drawn pathway maps representing exiting
knowledge of the molecular interaction and reaction networks. We
mapped all items (isoforms, TFs and SFs) in TSNs to their
ENTREZ ID and gathered all KEGG pathways from http://
www.genome.jp/kegg/. The enrichment of a network in a
pathway was evaluated using Fisher’s exact test.
We also used the Gene Ontology (GO) [37] database for
enrichment analysis. This project defines GO terms and structures
GO ontology as a directed acyclic graph through which each term
has relationships to one or more other terms in the same domain.
We downloaded GO biological processes through package
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STAT family. Like EGR1, the STAT family is also involved
in cell growth, differentiation, and survival and plays a role as
candidate regulator in almost one third of our networks. This
group of factors is typically oncogenic through the constitutive
activation of tyrosine kinase. The most canonical pathway for the
STAT family is FLT3 signaling in hematopoietic progenitor cells.
This relationship appeared in our network 18. In this network, two
STATs were predicted to regulate the expression of FLT3.
Though FLT3 positively regulates the tyrosine phosphorylation of
STAT proteins in the FLT3 signaling pathway, STATs are still on
the card to form signaling by regulating the expression level of
FLT3 through an auto-regulatory loop. He et al. [40] discussed a
positive auto-regulatory loop in the Jak-STAT pathway. STAT1/
3 in this loop tends to induce the expression of various components
of the Jak-STAT pathway to strengthen the signaling. Over
activation of FLT3 via the ITD mutation is related to the
pathogenesis of AML/MDS and is an adverse prognosis marker.
SRSF11. Recent studies reported some recurrent mutated
splicing factors in MDS [16,41,42]. These mutated genes,
including U2AF35, ZRSR2, SRSF2, SF3B1, SF3A1, SF1,
U2AF65 and PRPF40B were involved in multiple components
of the RNA splicing mechanism. However, none of these splicing
factors were recurrently mutated in our MDS cases.
We downloaded splicing factors from RBPDB [43] and checked
for alternative splicing. Among these 40 splicing factors, SRSF11
showed isoform switching in 7 of 20 MDS samples (Figure 2A),
including 4 RAEBs used to build our model, one RCMD, one
AML with MDS and one MDS for which the subtype is unknown.
According to the annotation information from the UCSC
database, the SRSF11 gene has eight isoforms, three of which
(uc001deu.2, uc001dev.3, uc009wbj.1) are highly expressed in our
samples. Isoform uc001deu.2 and uc001dev.3 have evidence at the
protein level (called p54, Uniprot ID Q05519), while the protein of
uc009wbj.1 has not been found yet. Although the total expression
levels of these three isoforms were almost the same in MDS and
control samples, 2 isoforms (uc001deu.2, uc001dev.3) were highly
expressed in MDS samples, whereas the uc009wbj.1 isoform was
highly expressed in control (average expression values). The
shorter amino acid chain from uc009wbj.1 only contained the
RRM (RNA recognition motif), while p54 not only contained
RRM at the N-terminal but also had a C-terminal RS domain.
This domain promotes protein-protein interactions to facilitate
recruitment of the spliceosome [7,44,45] (Figure 2B). These two
kinds of splicing factors (with or without SR domain) exhibit two
different functions. One is RS-domain dependent (recruiting
function) and the other is RS-domain independent (antagonist
function) [46]. Hence, we hypothesized that, in MDS cases, the
recruiting function of SRSF11 was enhanced and the antagonizing
splicing inhibitors was weakened. However, we needed further
data to evaluate the effect of this splicing switch.
To validate the abnormal expression of some isoforms, reverse
transcription polymerase chain reaction (RT-PCR) techniques
(File S1) were used to measure the expression level of three
isoforms from three SR proteins, including one isoform (uc001deu.2, refseq ID: NM_001190987) of SRSF11, one isoform
(uc001xlp.3, refseq ID: NM_006925) of SRSF5 and one isoform
(uc003jun.2, refseq ID: NM_080743) of SRSF12. CD34+ and
CD34- cells were sorted and CD342/CD3+ cells were further
separated with CD34 and CD3 magnetic beads (Miltenyi Biotec,
Auburn, CA). Total cellular RNA was extracted and cDNA was
synthesized as described in [47]. We chose primer 59-GCCTGGGCTGGAGGACAGAGA-39 and 59-TGCTCGGGTTCTCGCTCTTGATTG-39 for SRSF11 (NM_001190987),59- TGCGTCAGTTGTGGAGTGGCG-39 and 59-CGGCTAGTAC-

GOSim [38] for R language. Considering the size of our
regulatory networks, we filtered out GO biological processes
involving more than 100 genes or fewer than 10 genes. Fisher’s
exact test was performed using enrichment analysis function
(GOenrichment) in the GOSim package.

Results
To demonstrate how our method works, we first looked at
results of linear regression. After regression and model selection,
31 networks were obtained. Three co-expressed groups that did
not fit the linear model well were removed. Table 1 lists the gene
names of each co-expressed group and the corresponding TFs and
SFs identified by our method. Here we choose Network 1 as an
example for further explanation (Table 4). In this network, there
are 12 target co-expressed isoforms. For convenience, we used
gene names instead of isoform names. The LARS algorithm
identified 5 transcription factors and 5 splicing factors that may
regulate their expression. The adjusted coefficient of determination (adjusted R squared) is 0.991, which means expression of
these co-expressed isoforms was well fitted by their interaction
with the selected factors. Coefficients in regression are indicators of
contribution from corresponding factors. Factors with higher
coefficients, such as MBNL1, PSF, Sam68 and SRp38, predominate in influencing expression of this group of isoforms. On the
other hand, factors with lower coefficients, such as FOX factors
and Blimp-1, contribute less to determining expression of their
targets. Some of these coefficients are negative, which means these
factors may inhibit these isoforms’ expression. Details of the
regression coefficients are also listed (Table 4). Many factors may
be involved in the expression of these isoforms. Here, LARS only
selected the most representative ones that not only could regulate
the expression of these isoforms linearly but also did not suffer
from an over-fitting problem.
We also checked all the differentially expression isoforms using
Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/
index.html). In all 14 genes (FLT3, KIT, RPL13A, RPL3, RPL6,
RPL7, RPS14, RPS15A, RPS16, RPS19, RPS20, RPS4X, RPS6
and RUNX1) had been reported in MDS. Our isoform analysis
asserted that they all experienced alternative splicing. However
when we used traditional gene array analysis (7 MDS cases, 7
controls downloaded from Gene Expression Omnibus [Gene
Expression Omnibus number: GSE16236]), only 2 were recognized as being differentially expressed. This result demonstrated
that using only gene expression analysis is not sufficient. Isoform
and splicing analysis provides more information about gene
profiles and their regulatory mechanism.

MDS-related Factors
We then analyzed the transcription and splicing factors detected
by our method. Some of these factors have already been linked
with MDS or cancers in the literature, while others, such as
SRSF11, may be candidate factors that need further validation.
EGR1. The early growth response gene EGR1 appeared in
58% (18 of 31) of our networks. This factor plays important roles
in the regulation of cell growth, differentiation, and survival and
has been confirmed as a candidate tumor suppressor gene within
the commonly deleted segment of 5 q in MDS. However,
accumulating evidence now indicates that it can act a tumor
promoter in some cancer, such as prostate [39]. None of our MDS
samples are del(5 q), the EGR1 was overexpressed in all disease
samples compared to controls,. This suggests that EGR1 plays a
significant role in the development of MDS and that its function in
non-del(5 q) MDS needs further study.
PLOS ONE | www.plosone.org
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TTCCGGACGGGG-39 for SRSF5 (NM_006925), 59-CGGGAGACGGAGCGAGTCCA-39 and 59- TCCTCAGGCCTGG
TGGCGTC-39 for SRSF12 (NM_080743), 59-TTCGGAACTGA
GGCCATGAT-39 and 59-TTTCGCTCTGGTCCGTCTTG-39
for human 18SrRNA as the house keeping gene. The amplification process was conducted on the LightCycler with FastStart
DNA Master SYBRHGreen (Roche Applied Science, Indianapolis,
IN). All three isoforms, tended to be highly expressed in MDS
(Figure 2C), consistent with the observation that increased
expression of SR proteins usually correlates with cancer progression [48].
We also downloaded the protein expression profile of SRSF11
from the Model Organism Protein Expression Database (MOPED). We found that SRSF11 protein is highly expressed in
hematologic diseases (Figure 2D). It appears that the higher
expression of SRSF11 protein is due to the higher expression of
uc001deu.2 and uc001dev.3.

ratio of the isoforms produced by the alternative splicing of
SFRS11’s pre-mRNA is significantly different in controls and
MDS samples. This provided evidence that aberrant expression
and regulation of splicing factors may result in the deregulation of
splicing in diseases. Overall, our method is a good choice to detect
these disease-related factors.
In addition, this study offered a method to construct transcription
and splicing networks. Taking network 18 (Table 1) as an example.
We first input the target genes (DEIs) into the IPA system, and
found that these genes are enriched in hematological system
development and function, gene expression and cellular development networks. In order to look into the details, only a sub graph
(dark nodes in the middle of Figure 3) was displayed. Then we
added TFs and SFs to demonstrated regulatory relation. All these
edges between target genes and factors (TFs and SFs) were
determined based on the interaction strength matrix. Although
the connection between factors and target genes were determined
by our algorithm instead of experiments, some of them were
supported by literatures. For example p53 is one of the most
important tumor suppressors. In our network, it was connected with
the IFI16 (interferon-inducible myeloid differentiation transcriptional activator), which was consistent with the results in [50]. Those
previous experiments indicated that p53 could up-regulate IFI16,
and that functional interactions between IFI16 protein and p53
contributed to cellular senescence. The relationship between the
FLT and the STAT family was supported by the FLT signaling
pathway. Though FLT3 is upstream of the STAT family, it is very
likely that a regulatory loop like in the Jak-STAT pathway [40]
exists. In myeloid progenitor cells, Egr-1 bound to the Egr-1
promoter [51]. The regulation of STAT1 to EGR1 has also been
postulated [52]. However, some novel connections that have not yet
been reported, and their reliability needs further validation.
We suggested that splicing factor SRSF11 might function
differently in MDS patients and controls. To comprehensively
examine its target genes, we screened the whole genome using its
reported motif and found a number of putative binding sites.
Conservation scores for each binding site were also computed to
control the false positive rate. Only one-third of hits with the
highest conservation scores were kept for further analysis. Finally,
we obtained 1148 conserved binding sites, corresponding to 158
genes. They were all putative targets of SRSF11. All these genes
were analyzed using IPA software. The associated network with
the highest scores were those involved in cellular development,
cellular growth and proliferation and cell morphology. A total of
29 genes were associated with cancers, and 12 were associated
with hematological disease, including the MTOR gene which is in
the Akt/mTOR pathway and is critical for cell survival and
proliferation in high-risk MDS patients [53]. Since the Akt/
mTOR has been advised as a therapeutic target for treating MDS,
our study suggested that its abnormality might be related with the
splicing switch of SRSF11.

Enrichment Analysis
To evaluate the biological function of these 31 networks, we
comprehensively analyzed their enrichment in KEGG pathways
and GO biological process terms using the Fisher-exact test. Twenty
(64.5%) of 31 networks were enriched in at least one KEGG
pathway with an FDR-corrected q-value,0.05. Table 5 lists the
MDS-related networks. The most enriched pathway is herpes
simplex infection in which splicing factors are extensively involved.
The second most enriched pathway is pathway in cancer. This is a
very general pathway including many diseases, including AML, due
to its important role in proliferation. There were also two networks
(NT18 and NT20) enriched in the acute myeloid leukemia pathway,
the PPAR signaling pathway and the Jak-STAT signaling pathway.
Though these pathways are reported with AML, our RAEB subtype
which has high risk of transforming to AML should a have similar
gene profiles with AML.
These networks were also enriched in 42 different GO
biological processes and 21 (68%) were enriched in at least one
process (Pvalue ,1e-4). Table 6 lists three selected networks and
their corresponding biological processes. Most of these biological
processes are related with splicing, including mRNA 59-splice site
recognition, regulation of RNA splicing, and mRNA 39-end
processing.

Discussion
From transcription to translation, gene expression is modulated
by many factors. Traditional predictive models of gene expression
only consider the transcription. In this study, we proposed a
systematic approach to recognize putative regulatory factors
regulating co-expressed isoforms that were differentially expressed
in disease. In case of MDS, the most recurrent transcription factors
involved in regulating abnormally expressed genes were NKX2-5
and Egr-1. NKX2-5 is a master transcription factor. EGR1 is a
candidate tumor suppressor gene within the commonly deleted
segment of 5 q and has been claimed to play a role in murine
leukemogenesis and development of AML/MDS characterized by
abnormalities of chromosome 5. Its overexpression in our MDS
cases indicates it may also act as tumor promoter as in prostate
cancer. Additionally, we found some putative MDS-associated
splicing factors, e.g. SF2 and SRSF11. They were highly related
with developmental pathways that were deregulated in MDS
cases. Previous reports confirm that SF2 is an oncogene and
overexpression of SF2 may cause some tumor suppressors to lose
function [49]. Our MDS samples verified its overexpression. We
also detected a significant splicing switch of factor SFRS11. The

PLOS ONE | www.plosone.org
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